Literature DB >> 12773446

An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI.

Peter Platteau1, Els Laurent, Carola Albano, Kaan Osmanagaoglu, Valérie Vernaeve, Herman Tournaye, Michel Camus, André Van Steirteghem, Paul Devroey.   

Abstract

BACKGROUND: A pen device, similar to an insulin pen, has been recently marketed for the administration of follitropin beta in cartridges. A randomized controlled trial was performed to compare the efficacy and convenience of this pen device delivering follitropin beta with a conventional syringe delivering follitropin alpha.
METHODS: A total of 200 patients needing IVF/ICSI treatment and willing to self-inject were enrolled in the study. All subjects had ovarian stimulation according to a long protocol and were randomized to the pen or the conventional syringe group during down-regulation by means of a computer-generated randomization list using random numbers. Patients were asked to fill in a daily local tolerance book after each injection. On the day of hCG the patients scored a Visual Analogue Scale (VAS) for pain and convenience.
RESULTS: The average duration, total dose of recombinant FSH and number of cumulus oocyte complexes retrieved were 10.8/12.0 days (P = 0.001), 1880/2226 IU (P < 0.001) and 15.2/13.1 respectively in the pen device and conventional syringe groups; the presence of pain after the daily injection was significantly higher in the conventional syringe group (P = 0.027); the visual analogue scale score was similar for pain but significantly more convenient for the pen device (P < 0.001). The live birth rate per embryo transfer was 32.9 and 34.4% respectively in the pen device and conventional syringe groups.
CONCLUSIONS: Self-injection with the pen device is safe and easy, more convenient and less painful for the patient, requires less FSH and shortens the treatment duration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773446     DOI: 10.1093/humrep/deg234

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  A questionnaire-based survey to assess patient satisfaction, ease-of-learning, ease-of-use, injection site pain and overall patient satisfaction of the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen compared with other systems of gonadotrophin administration.

Authors:  Takafumi Utsunomiya; Atsushi Tanaka; Kenichi Tatsumi; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-11-20       Impact factor: 5.211

2.  Willingness to pay and conjoint analysis to determine women's preferences for ovarian stimulating hormones in the treatment of infertility in Spain.

Authors:  A Palumbo; P De La Fuente; M Rodríguez; F Sánchez; J Martínez-Salazar; M Muñoz; J Marqueta; J Hernández; O Espallardo; C Polanco; S Paz; L Lizán
Journal:  Hum Reprod       Date:  2011-05-10       Impact factor: 6.918

3.  Managing infertility with the follitropin alfa prefilled pen injector - patient considerations.

Authors:  Klaus Bühler
Journal:  Ther Clin Risk Manag       Date:  2015-06-29       Impact factor: 2.423

Review 4.  Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.

Authors:  Rogério de Barros F Leão; Sandro C Esteves
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

5.  Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment.

Authors:  Peter J Illingworth; Robert Lahoud; Frank Quinn; Kendal Chidwick; Claire Wilkinson; Gavin Sacks
Journal:  Patient Prefer Adherence       Date:  2014-06-05       Impact factor: 2.711

Review 6.  A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.

Authors:  Colin H Ridyard; Dalia M M Dawoud; Lorna V Tuersley; Dyfrig A Hughes
Journal:  Patient       Date:  2016-08       Impact factor: 3.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.